Do You Need to Call 911 After Using Gvoke?
No, you do not automatically need to call 911 after using Gvoke (glucagon injection for severe hypoglycemia). Call 911 only if the person remains unconscious or unresponsive after 15-20 minutes, symptoms do not improve, or severe symptoms like seizures or breathing problems persist. Gvoke is designed for emergency use at home or in public, followed by eating carbs once alert.
What Instructions Say to Do Right After Gvoke?
After injecting Gvoke:
- Turn the person on their side to prevent choking if they vomit.
- Feed them fast-acting carbs (15g, like glucose tabs or juice) as soon as they wake up and can swallow.
- Monitor blood sugar every 15 minutes; repeat Gvoke if still below 70 mg/dL after 15 minutes.
- Contact their doctor or go to the ER if recovery takes longer than expected.
This follows FDA-approved labeling for Gvoke HypoPen and prefilled syringe.
When Exactly to Call 911 or Go to ER?
Call 911 immediately if:
- No response 15 minutes post-injection.
- Repeated hypoglycemia episodes.
- Signs of overdose (nausea, vomiting are common but mild; severe cases rare).
- Allergic reaction (rash, swelling, breathing issues).
- Person has head injury, alcohol intoxication, or other complications.
About 6% of users need medical follow-up due to poor response.
What Happens if You Don't Call When Needed?
Delaying can lead to brain damage, coma, or death from untreated low blood sugar. Gvoke buys 15 minutes, but unresponsive cases often signal underlying issues like insulin overdose requiring IV glucose.
Gvoke vs. Other Glucagon Options—like Glucagon Emergency Kit?
Gvoke is faster (ready-to-use, no mixing) and has fewer steps than older kits like Lily's Glucagon. Both require similar post-use monitoring and 911 criteria—no difference in when to seek emergency help. Gvoke is shelf-stable at room temperature up to 12 months longer.
[1] Gvoke Prescribing Information, Xeris Pharmaceuticals (fda.gov label, 2023).
[2] American Diabetes Association Hypoglycemia Guidelines (diabetes.org, 2024).
[3] DrugPatentWatch.com (Gvoke patents expire 2031-2034; no impact on emergency use).